BHCM
ITCI

Boulder Hill Capital Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Boulder Hill Capital Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-7,500
Closed -$349K – 231
2022
Q3 		$349K Buy
+7,500
New +$392K 0.26% 100

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Boulder Hill Capital Management's ITCI Position: Q4 2022 in Review

Boulder Hill Capital Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q4 2022, closing a stake of 7,500 shares — an estimated $349K sold.

Boulder Hill Capital Management first reported a position in ITCI in Q3 2022 and held it in 1 quarter. The position peaked at $349K in Q3 2022. 283 funds tracked by Wall St. Rank hold ITCI as of Q4 2022.

  • Boulder Hill Capital Management reported no remaining Intra-Cellular Therapies Inc. position as of Q4 2022 after selling out during the quarter.
  • Boulder Hill Capital Management sold 7,500 Intra-Cellular Therapies Inc. shares in Q4 2022, an estimated $349K.
  • Boulder Hill Capital Management first reported a position in Intra-Cellular Therapies Inc. in Q3 2022 and held it in 1 quarter.
  • Boulder Hill Capital Management's Intra-Cellular Therapies Inc. position peaked at $349K in Q3 2022.
  • 283 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2022.

Based on Boulder Hill Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.